Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perindopril added to nivolumab and ipilimumab for unresectable or metastatic melanoma
ACTRN12621000156886Phase 2Recruiting
- Sponsor
- Calvary Mater Newcastle
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perindopril in melanoma, sponsored by Calvary Mater Newcastle. Primary endpoint: Incidence of treatment-related adverse events. Started Aug 2021; status: recruiting.
02
Drugs
perindopril
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12621000156886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000156886.